Nanexa AB
Research Nanexa AB (NANEXA) on Bullrun: market cap SEK 885.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNANEXA
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 885.13M
- Financial periodQ1 2026
- RevenueSEK 1.63M
- Net income-SEK 14.02M
- Free cash flow-SEK 10.86M
- Gross margin375.2%
Valuation Snapshot
latest market cap is SEK 885.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 36.15M | -SEK 11.39M | -SEK 26.21M | 154.7% | -0.08 | SEK 44.57M | SEK 2.20M | SEK 101.53M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | SEK 885.13M | n/a | n/a | n/a |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nanexa AB's market cap?
Nanexa AB's market capitalization is SEK 885.13M.
What does Nanexa AB do?
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances.